From: Convalescent anti-SARS-CoV-2 plasma for the treatment of patients with COVID-19: a retrospective study RESCOVID-19
number of patients enrolled (CP-group) (n = 406)
adverse reactions (n, %)
overall
9
2.2
circulatory overload
4
1.0
allergic reaction
2
0.5
febrile reaction
3
0.7